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Abstract
Background/objectives: Hypertension treatment reduces cardiovascular
events. However, uncertainty remains about benefits and harms of
deintensification or further intensification of antihypertensive medication
when systolic blood pressure (SBP) is tightly controlled in older multimorbid
patients, because of their frequent exclusion in trials. We assessed the associa-
tion of hypertension treatment deintensification or intensification with clinical
outcomes in older adults with tightly controlled SBP.
Design: Longitudinal cohort study (2011–2013) with 9-month follow-up.
Setting: U.S.-nationwide primary care Veterans Health Administration
healthcare system.
Participants: Veterans aged 65 and older with baseline SBP <130 mmHg and
≥1 antihypertensive medication during ≥2 consecutive visits (N = 228,753).
Exposure: Deintensification or intensification, compared with stable treatment.
Main outcomes and measures: Cardiovascular events, syncope, or fall injury,
as composite and distinct outcomes, within 9 months after exposure. Adjusted
logistic regression and inverse probability of treatment weighting (IPTW, sensitiv-
ity analysis).
DOI: 10.1111/jgs.17295
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Results: Among 228,753 patients (mean age 75 [SD 7.5] years), the composite
outcome occurred in 11,982/93,793 (12.8%) patients with stable treatment,
14,768/72,672 (20.3%) with deintensification, and 11,821/62,288 (19.0%) with
intensification. Adjusted absolute outcome risk (95% confidence interval) was
higher for deintensification (18.3% [18.1%–18.6%]) and intensification (18.7%
[18.4%–19.0%]), compared with stable treatment (14.8% [14.6%–15.0%]),
p < 0.001 for both effects in the multivariable model). Deintensification was
associated with fewer cardiovascular events than intensification. At baseline
SBP <95 mmHg, cardiovascular event risk was similar for deintensification
and stable treatment, and fall risk lower for deintensification than intensifica-
tion. IPTW yielded similar results. Mean follow-up SBP was 124.1 mmHg for
stable treatment, 125.1 mmHg after deintensification (p < 0.001), and
124.0 mmHg after intensification (p < 0.001).
Conclusion: Antihypertensive treatment deintensification in older patients
with tightly controlled SBP was associated with worse outcomes than continu-
ing same treatment intensity. Given higher mortality among patients with
treatment modification, confounding by indication may not have been fully
corrected by advanced statistical methods for observational data analysis.
KEYWORD S
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INTRODUCTION
Hypertension affects over 70% U.S. adults after the age
of 60 years.1 While there is strong evidence that modest
blood pressure (BP) control reduces cardiovascular risk
in older adults, intensive control for those patients
remains controversial. In the HYVET trial, a target sys-
tolic BP (SBP) <150 mmHg reduced cardiovascular
event relative risk by 34% in patients aged 80 and
older.2 In the SPRINT trial, a target SBP <120 mmHg
reduced cardiovascular disease and mortality, even in
patients aged 75 and older, but adverse events were
increased.3,4 After SPRINT, U.S. hypertension guide-
lines were revised to lower BP targets,5,6 although a
meta-analysis (including SPRINT) found no reduction
in mortality or major cardiovascular events in trials
where patients with a baseline SBP <140 mmHg were
treated to lower targets.7 However, because older
multimorbid patients were often excluded from trials
(e.g., high-fall risk patients, such as patients with
dementia or living in nursing home, were excluded in
HYVET and SPRINT),2,3 little is known about optimal
BP goals for a real-world population that includes indi-
viduals at high risk of adverse events.8
In several observational studies, patients with SBP
<130 mmHg had higher rates of cardiovascular events,
mortality, and cognitive impairment, supporting a J-curve
hypothesis, i.e., an increased risk of cardiovascular events
not only for hypertensive BP values, but also when BP
Key Points
• Deintensifying antihypertensive medication in
older adults with systolic blood pressure (SBP)
<130 mmHg was not associated with better
outcomes, except when baseline SBP was
<95 mmHg.
• It is possible that some patients deintensifying
treatment at low SBP were addressing
unobservable symptoms related to falling, thus
confounding our observational study. There-
fore, a trial is needed.
Why Does this Paper Matter?
Benefits and harms of deintensifying antihyper-
tensive medication in older adults with low SBP
is uncertain.
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is very low.9,10 Among Medicare patients with hyperten-
sion, patients taking antihypertensive medications were
also found to have a higher risk of serious fall injuries
compared with those not taking medication.11 A study
among 211,667 Veterans reported that almost 40% of
treated older multimorbid adults have a SBP
<120 mmHg, yet less than 20% of those with SBP
<120 mmHg received deintensification.12 Responding
to these observations, some studies have looked for
benefits of deintensification. The DANTE trial of
385 participants aged 75 and older found no change in
cardiovascular and cognitive outcomes 16 weeks after
deintensification,13 while two small studies reported
lower fall risk after deintensification.14,15 The OPTI-
MISE trial found that there was little difference in SBP
after deintensification (569 patients, ≥80 years, base-
line SBP <150 mmHg), but long-term clinical outcomes
were not reported.16
Accordingly, there remains uncertainty about the
potential benefits and harms of intensive BP control in
older adults with multimorbidity. Given recent evidence,
clinicians may fear that deintensification for older
patients with low SBP will lead to an increased risk of
cardiovascular events.17,18 Yet, some older adults fear
serious fall injuries as much as they fear cardiovascular
events.19 Nonetheless, the SPRINT trial, performance
measures, and lower BP targets in guidelines will inevita-
bly lead to more aggressive treatment of older patients,
potentially including those at high risk for adverse
events, to whom the guidelines may not explicitly apply.
We therefore examined the association between change
in hypertension treatment intensity and cardiovascular
events, syncope, and fall injuries, among over 200,000
older patients with treated BP in the Veterans Health
Administration (VHA), the largest U.S. integrated
health system. We focused on those outcomes because
they can significantly impact the functional status of
older patients. We hypothesized that hypertension treat-
ment deintensification would be associated with fewer
syncope and fall injury events, without increasing cardio-
vascular event risk in older adults with tightly
controlled SBP.
METHODS
Data from the study are not openly available to other
researchers due to protected patient information by the
VHA. Statistical codes can be provided by the corresponding
author upon request. The codes for the hypertension daily
dose (HDD, see below) and fall injury have been published
in open source format.20,21
Overall approach
We used data from electronic health records from the
national Department of Veterans Affairs (VA) healthcare
system from July 2011 through June 2013, linked to VA
and Medicare pharmacy and outcome data. In all Veterans
aged 65 and older with tightly controlled SBP, we first
assessed whether modifying the intensity of hypertension
treatment was associated with cardiovascular, syncope, and
fall injury events. Second, we assessed the effect of treat-
ment intensity modification on subsequent SBP.
Study population
The study included all patients aged 65 and older with
ongoing primary care at the VHA, a diagnosis of hyper-
tension, and tightly controlled SBP, defined as SBP
<130 mmHg with ≥1 antihypertensive medication on ≥2
consecutive visits (Figure 1). The 130 mmHg threshold
was chosen as being 10 mmHg below the recommended
SBP target at the study time (2011–2013).22 To increase
precision, we used mean SBP of the two visits to define
baseline SBP. This research was conducted under Human
Subjects review (VA IRB 2015-286).
Variable construction and definition
Using ICD-9 codes, we classified comorbidities into
chronic conditions, including general medical conditions,
cardiovascular risk factors, and geriatric conditions
(Table S1), and defined multimorbidity as ≥1 chronic
condition in addition to hypertension.23 We selected all
conditions potentially associated with our treatment
and/or outcomes of interest, as well as markers of patient
FIGURE 1 Study design. Eligibility was defined as two
consecutive visits with systolic blood pressure <130 mmHg and ≥1
antihypertensive medication within a 2-year period. Treatment
assignment was defined by calculating the difference (Δ) in dose
and medication count between day 0 (baseline) and day 90. The
follow-up was between 90 days and 1 year after baseline
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sickness or frailty. To capture antihypertensive treatment,
we applied an algorithm that we previously validated in
older Veterans, which uses VA and Medicare Part D
pharmacy fills to determine the most likely antihyperten-
sive medication on any day.24 We standardized doses to
HDDs, allowing comparison across medications.20 We
defined one HDD as half the maximum beneficial dose
demonstrated in trials (Table S2),25–27 and aggregated the
standardized doses to obtain total dose. For example,
hydrochlorothiazide 50 mg (maximal beneficial dose:
2 HDDs) with candesartan 16 mg (half maximal benefi-
cial dose: 1 HDD) would equal 3 total HDDs.
Our primary exposure of interest was a three-level
treatment strategy based on dose changes between base-
line and +90 days (Figure 1): deintensification (any
dose decrease), intensification (any dose increase), or
stable treatment intensity (no dose change). The 90-day
period was selected because it is the usual refill period.
To interpret our results in light of prior studies that
have historically reported the results of changes in med-
ication count only,13,14,28 we conducted sensitivity ana-
lyses that similarly defined treatment strategy by
modification in medication count.
The primary outcome was a binary composite outcome
of any inpatient (hospitalizations) or outpatient (emergency
department visits) encounter for acute cardiovascular
events, syncope, or fall injury, within 9 months after treat-
ment strategy assignment (i.e., 90–365 days after baseline,
Figure 1). Cardiovascular events included only acute diag-
noses of hemorrhagic and ischemic stroke, acute coronary
syndrome, and decompensated heart failure. We used
ICD-9 codes for cardiovascular events and syncope
(Table S3), and a validated algorithm for capturing compre-
hensive new fall injury events across inpatient and outpa-
tient care.21 We assessed cardiovascular events, syncope,
and fall injury separately as secondary outcomes to avoid
missing potential opposite associations, and because some
patients may value avoiding one event more than the
other.19
Statistical analyses
In order to estimate the association between treatment
intensity modification and outcome, we used a logistic
regression with categorical indicators for treatment strategy,
TABLE 1 Baseline characteristics according to treatment strategy







Age, mean (SD), years 74.9 (7.4) 75.6 (7.6) 75.2 (7.5)
Male 92,051 (98.1) 71,380 (98.2) 61,242 (98.3)
Baseline SBP, mean (SD), mmHg 117.5 (7.1) 115.6 (8.3) 116.9 (7.5)
≤110.0 mmHg 14,775 (15.7) 17,202 (23.7) 11,329 (18.2)
110.5–120.0 mmHg 41,238 (44.0) 31,225 (43.0) 27,113 (43.5)
120.5–129.0 mmHg 37,780 (40.3) 24,245 (33.3) 23,846 (38.3)
Chronic conditions
Number, mean (SD) 3.0 (3.1) 4.3 (3.6) 3.7 (3.5)
Multimorbiditya 70,850 (75.5) 62,013 (85.3) 50,573 (81.2)
Vascular disorderb 25,602 (27.3) 29,503 (40.6) 23,091 (37.1)
Heart failure or valve disorder 11,500 (12.3) 17,295 (23.8) 13,681 (22.0)
Diabetes mellitus, type II 29,341 (31.3) 28,859 (39.7) 23,689 (38.0)
Fall riskc 15,788 (16.8) 18,089 (24.9) 13,196 (21.2)
Antihypertensive medication
Total dose, mean (SD), HDD 2.2 (1.8) 2.9 (2.2) 2.3 (1.9)
Medication count, mean (SD) 2.2 (1.1) 2.8 (1.3) 2.6 (1.2)
Note: Dichotomous variables are presented as N (%), and continuous variables as mean with standard deviation.
Abbreviations: HDD, hypertension daily dose; No., number.
aHypertension with ≥1 additional chronic condition.
bCardiac, peripheral, and/or cerebral vascular disorder.
cFall risk included Parkinson's disease, peripheral neuropathy, ataxia, vertigo/dizziness, orthostatic hypotension, walking difficulty/gait abnormality/lack of
coordination, muscle weakness, syncope, history of fall (ICD-9 codes: 340–342.91, 356.XX, 357.XX, 386.XX, 438.2–438.22, 438.40–438.42, 438.84, 438.85, 458.0,
719.7, 728.87, 780.2, 780.4, 781.1, 781.2, 781.3, V15.88).
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adjusting for baseline covariates, which included age,
chronic conditions, baseline SBP, and baseline antihyperten-
sive medication dose. Since close proximity to death could
directly result in a general deintensification of preventive
medications, we did not include death as outcome, and the
analytic cohort included only patients who were survived
until end of follow-up (i.e., 365 days after baseline) (96.4% of
all identified patients). To reduce potential bias resulting
from deaths during the follow-up period, we weighted the
analyses by the inverse probability of survival. This main
model resulted in estimated marginal risk associated with
the three treatment strategies as if the patients who died
were included in the analysis and survived. Next, in order to
reduce bias resulting from patient factors associated with
deintensification (vs no deintensification), we conducted a
sensitivity analysis using inverse probability of treatment
weighting (IPTW) by propensity scores (PS). Models to
derive both survival and treatment weights included all
baseline covariates. Since patients with cardiovascular dis-
ease or heart failure may benefit from a lower SBP target,
we conducted a sensitivity analysis assessing patients with
and without cardiovascular disease or heart failure sepa-
rately. All outcome models included two interaction terms,
between age and baseline SBP (to account for and nonlinear
effect of SBP with increasing age) and between treatment
strategy and baseline SBP (to account for effect modification
that baseline SBPmight have on treatment effect).
To assess the association between treatment strategy
and follow-up SBP, we calculated the mean SBP across all
visits during follow-up period, and compared changes in
mean SBP between baseline and follow-up, according to
treatment strategy and adjusting for baseline SBP. We
compared proportions with ≥10 mmHg change in mean
SBP using chi-square tests.
Details of the statistical analyses are provided in File
S1. All analyses were performed with Stata/MP 15.1
(StataCorp) and SAS Enterprise Guide 7.1 (SAS Institute).
RESULTS
After excluding 8,461 (3.6%) patients with missing out-
come data due to death before end of follow-up, 228,753
patients (mean age 75.2 [SD 7.5] years, 98.2% males) were
included in the analytic cohort. Mean baseline SBP was
116.7 (SD 7.6) mmHg, and 183,436 (80.2%) patients had
multimorbidity. Baseline characteristics according to
treatment strategy are presented in Table 1.
Deintensification was observed in 72,672 (31.8%) patients,
and intensification in 62,288 (27.2%) patients. Patients
with deintensification had the highest mortality rate
(4.1%), followed by those with intensification (3.2%), and
stable treatment (1.8%, p < 0.001).
Association of deintensification and
intensification with the composite
outcome
The primary composite outcome occurred in 38,571
(16.9%) patients, including 25,601 cardiovascular events,
3,438 syncope episodes, and 20,282 fall injuries
(Table S4). The composite outcome occurred in 12.8%
(11,982/93,793) of patients with stable treatment, 20.3%
(14,768/72,672) with deintensification, and 19.0%
(11,821/62,288) with intensification.
Adjusted absolute outcome risk (95% confidence inter-
val [CI]) was higher for deintensification (18.3% [18.1%–
18.6%]) and intensification (18.7% [18.4%–19.0%]), com-
pared with stable treatment (14.8% [14.6%–15.0%]),
p < 0.001) (Table 2 and Figure 2A). Although the overall
composite outcome risk associated with deintensification
was higher compared with stable treatment, the risks asso-
ciated with these two treatment strategies were similar in
those with low baseline SBP (<95 mmHg), while the risk
TABLE 2 Adjusted outcome risks according to treatment
strategy (No. = 228,753 patients)





Stable treatmentb 14.8 (14.6 to 15.0) 16.2 (16.0 to 16.3)
Deintensification 18.3 (18.1 to 18.6) 19.8 (19.4 to 20.3)
Intensification 18.7 (18.4 to 19.0) 22.1 (21.5 to 22.7)
Cardiovascular event
Stable treatmentb 9.1 (8.9 to 9.2) 10.5 (10.4 to 10.6)
Deintensification 12.3 (12.0 to 12.5) 13.4 (13.1 to 13.8)
Intensification 13.2 (12.9 to 13.4) 16.7 (16.2 to 17.3)
Syncope
Stable treatmentb 1.3 (1.2 to 1.3) 1.4 (1.4 to 1.5)
Deintensification 1.7 (1.6 to 1.8) 1.8 (1.6 to 1.9)
Intensification 1.6 (1.5 to 1.7) 1.8 (1.6 to 2.0)
Fall injury
Stable treatmentb 8.3 (8.1 to 8.5) 8.7 (8.6 to 8.8)
Deintensification 9.7 (9.5 to 9.9) 10.2 (9.9 to 10.5)
Intensification 9.1 (8.9 to 9.4) 9.9 (9.4 to 10.4)
Abbreviation: CI, confidence interval.
aBased on logistic regression model weighted to account for missing
outcome. The model included interaction terms between age and systolic
blood pressure and between systolic blood pressure and treatment strategy,
and was also adjusted for baseline antihypertensive medication dose and for
chronic conditions (Table S1).
bReference group, defined as no dose or medication count change,
respectively, is displayed in italic to facilitate reading.
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associated with deintensification was higher than that asso-
ciated with stable treatment with higher baseline SBP
(Figure 2A). In the sensitivity analysis with treatment strat-
egy defined using medication count change, adjusted out-
come risk (95% CI) was 16.2% (16.0%–16.3%; reference) for
stable treatment, 19.8% (19.4%–20.3%; p < 0.001) for
deintensification, and 22.1% (21.5%–22.7%; p < 0.001)
for intensification (Table 2 and Figure S1A).
Association of deintensification and
intensification with cardiovascular events,
syncope, and fall injuries as separate
outcomes
The relationship between treatment modification and
cardiovascular events was similar to the main analysis
of the composite outcome, except for that for patients
with baseline SBP <95 mmHg, there was no cardiovas-
cular difference in risk associated with deintensification
and stable treatment (Figure 2B, Table 2 and
Figure S1B, Table S5). Compared with intensification,
cardiovascular event risk was 1.0% (95% CI 1.4% to
0.6%; p < 0.001) lower for dose deintensification, and
3.7% (95% CI 4.5% to 3.0%; p < 0.001) lower for med-
ication count reduction. Both deintensification and
intensification were associated with an increased syn-
cope risk across all baseline SBP values, compared with
stable treatment. Overall, deintensification was associ-
ated with a 1.5% (95% CI 1.1%–1.9%; p < 0.001) greater
risk of fall injury compared with stable treatment.
However, at low baseline SBP (<95 mmHg),
deintensification was associated with the lowest fall risk
(Figure 2D).
FIGURE 2 Adjusted absolute risk for (A) composite outcome, (B) cardiovascular event, (C) syncope, and (D) fall injury, according to
dose change and baseline systolic blood pressure. Based on logistic regression models weighted to account for missing outcome. The
models included interaction terms between age and systolic blood pressure and between systolic blood pressure and treatment strategy,
and were also adjusted for baseline antihypertensive medication dose and for chronic conditions (Table S1)
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Sensitivity analysis: inverse probability
weights to reduce bias of patient
characteristic leading to different
treatments
We found that IPTW was appropriate, improving balance
in covariates between treatment groups from a maximum
standardized difference of 36.9% to 4.2% (Figures S2–S5).
After applying the IPTW, we found no differences with
the main analyses (Table S5).
Sensitivity analysis: patients with versus
without cardiovascular disease or heart
failure
Patients with cardiovascular disease or heart failure had
an absolute outcome risk (95% CI) of 21.5% (21.1%–
22.0%) for stable treatment, 26.1% (25.6%–26.5%) for
deintensification, and 27.2% (26.7%–27.7%) for intensifi-
cation. Patients without cardiovascular disease or heart
failure had an absolute outcome risk (95% CI) of 10.3%
(10.1%–10.6%) for stable treatment, 13.2 (12.9%–13.5%)
for deintensification, and 13.0 (12.7%–13.4%) for
intensification.
Follow-up SBP
Mean SBP at baseline was low and increased over the
1-year follow-up in all treatment groups: from 117.5 to
124.1 mmHg for stable treatment, 115.7 to 125.1 mmHg
for deintensification, and 117.0 to 124.0 mmHg for inten-
sification (p < 0.001), consistent with regression to the
mean (Table S6A). A ≥10 mmHg decrease between mean
baseline and follow-up SBP was less frequent after
deintensification (5.7%; p < 0.001), and more frequent
after intensification (7.5%; p < 0.001), compared with sta-
ble treatment (6.7%; reference); a ≥10 mmHg increase
was observed in 45.9% of patients with deintensification,
38.6% with intensification, and 37.0% with stable treat-
ment (p < 0.001; Table S6B). Similar findings were found
using medication count instead of dose modification.
DISCUSSION
In this large-scale study of over 228,000 older adults with
tightly controlled SBP at baseline, we hypothesized, but
did not find, that deintensification would be associated
with a short-term reduction in injurious falls and syn-
cope. The risk of cardiovascular events and fall injury
increased when baseline SBP was low, while syncope risk
varied little by baseline SBP. Deintensification was asso-
ciated with fewer cardiovascular events than intensifica-
tion, and there was a pattern for a lower risk of
cardiovascular events and fall injury when baseline SBP
was very low. Changes in SBP relative to baseline were
small and did not vary by treatment strategy. Mean SBP
remained <130 mmHg during follow-up for all treatment
strategies.
We report our findings in the context of prior litera-
ture. Previous studies found that SBP <130 mmHg was
associated with higher rates of cardiovascular events,
mortality, and cognitive impairment,9,10 and that antihy-
pertensive medications were associated with a higher risk
of serious fall injuries.11 We observed a pattern for fewer
fall injuries after deintensification compared with stable
treatment only below baseline SBP 95 mmHg, which is
consistent with a study reporting 11.4% lower fall risk
after deintensification in nursing home patients with
baseline 80–100 mmHg, but non-significant association
at 101–120 mmHg.14 Another study found a 0.35 hazard
ratio for recurrent fall after withdrawing fall-risk increas-
ing medications in 67 patients.15 The results of those
studies, compared with ours, may be explained by their
focus on high fall-risk patients, intervention on several
fall-risk increasing medications, or assessment of falls
not leading to medical visit. While we observed an
increased fall risk after deintensification at baseline SBP
95–130 mmHg, our findings may be related to
unmeasured confounders (e.g., uncaptured higher fall
risk in patients with treatment modification, treatment
change related to other fall-risk increasing medications).
In the DANTE trial, there was no difference in cardio-
vascular outcomes after deintensification, but patients
with serious cardiovascular disease were excluded, mean
baseline SBP was 148 mmHg, and follow-up was limited
to 16 weeks.13 In SPRINT, reducing SBP from a mean of
139.7 to 121.5 mmHg decreased cardiovascular events
and mortality, even in patients aged 75 and older.3,4
However, none of the patients we studied would have
been eligible for SPRINT, because their baseline SBP was
already treated to <130 mmHg. Moreover, we included
patients who were excluded in SPRINT (diabetes mellitus
type 2, stroke, heart failure, dementia, 65–74 years with-
out cardiovascular history). In this population, we found
that deintensification was associated with worse out-
comes, compared with a strategy of maintaining antihy-
pertensive treatment intensity, except when baseline SBP
was very low.
Our hypothesis that deintensification would be asso-
ciated with fewer syncope and fall injuries, without
increasing cardiovascular event risk, was not confirmed.
Although we used robust methods for observational data
analysis, we could not control for all confounders. It is
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possible that continued unmeasured confounding and/or
confounding by indication may have led to our results,
despite these advanced methods. Baseline characteristics
and death rates during follow-up indeed suggest that
deintensified and intensified patients were sicker than
those with stable treatment. One-year mortality was
indeed more than twice as high among patients who
deintensified, compared with those with stable treatment.
Furthermore, the association of treatment modification
with adverse outcomes was greater in patients with car-
diovascular disease or heart failure. This suggests that
patients with treatment intensity modification had a
higher baseline outcome risk. Greater outcome risk and
more severe disease may have driven both treatment
intensity modification and outcome occurrence. In addi-
tion, unlike a trial where patients would have been
assigned to deintensification or intensification based on
their baseline SBP in otherwise stable clinical conditions,
we could not capture reasons other than SBP that may
have led to treatment modification if they were not coded
(e.g., change in control of heart failure or atrial fibrilla-
tion, end-of-life, medication adverse effects). These rea-
sons could also have contributed to treatment
intensification despite low baseline SBP. The outcomes
may have been different in a randomized controlled trial
than in this retrospective study using administrative data.
Another possible explanation is that any change to a
medication regimen is in itself a significant risk for older
patients. Polypharmacy and age-related changes in medi-
cation metabolism and elimination can make
multimorbid older patients more sensitive to medication
adverse effects and interactions.29 The relatively small
differences in follow-up SBP across treatment groups
themselves argue that the differences in outcomes
observed for those with a change in their regimen versus
stable treatment was mediated through something else
than the BP level alone.
Strengths and limitations
Our study has several strengths. First, we included a far
larger number of patients than previous studies.14,16
Second, we used the best-available real-world data that
included clinical BP measurements, and a near-
universal data source on medication fills from the
largest U.S. healthcare system and Medicare. Third, we
simulated an experiment by assessing the association
between treatment modification and events occurring
after treatment modification, using advanced statistical
methods to reduce the risk of confounding: in the multi-
variable regression, we adjusted for a broad range of var-
iables, and we additionally conducted a sensitivity
analysis using IPTW to assure balance on average of all
of that wide range of measured covariates. Furthermore,
since proximity to death may lead to deintensification,
we additionally weighted the sample by the inverse
probability of survival. Fourth, unlike prior
studies,13,14,16,28 we quantified treatment intensity modi-
fication with two measures (standardized dose and med-
ication count), averaged two consecutive SBP
measurements to reduce measurement error in a key
baseline covariate, and used two consecutive visits to define
eligibility, according to both baseline SBP and medication, lim-
iting the risk of including patients without tightly controlled
SBP. Finally, we assessed multiple clinical outcomes over
9 months, while previous studies were limited to a few weeks,
or have not yet reported clinical outcomes.13–16
We must acknowledge some limitations. First, we
cannot exclude unmeasured confounding resulting from
bias in distributing the treatment approach in observa-
tional studies. We addressed this bias with two different
methods for causal inference in observational data
(regression adjustment in the main analysis and an IPTW
sensitivity analysis). The similar results of the IPTW, with
good PS and covariate balance, add validity to our results.
However, as discussed above, administrative data alone
cannot provide enough data for us to control for con-
founding by indication, and the small difference in SBP
suggests that the results were mediated through some-
thing else than BP alone. Second, pharmacy fill data do
not ascertain medication consumption. However, there is
no gold standard for medication consumption in outpa-
tient care, and prior research has proposed fills as a reli-
able source of data.30,31 Third, the use of administrative
data precluded our ability to ascertain the clinical reason-
ing behind any dose modification event. Fourth, the
study time frame (2011–2013) predates the newest guide-
lines (after the SPRINT trial), which lowered rec-
ommended SBP to <130 mmHg for most older adults.5
However, SBP target used by most healthcare systems
for performance measures was identical at the time of
the study to current measures (<140 mmHg).32–34 Fifth,
because our overarching interest was on clinical events
that can impact older adults' functional status, we
focused on cardiovascular events, syncope and fall inju-
ries. We cannot draw conclusions about other types of
outcomes such as acute kidney injury or electrolyte
abnormalities, events that were also increased by
SPRINT intervention.3 Finally, as all studies in older
Veterans, the results may not be generalizable to older
women. However, the great strengths for this dataset for
studying health systems outweigh this limitation. No
other national dataset exists and is compiled in a
national repository that includes medications, BP,
comorbid conditions, and outcomes.
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CONCLUSION
In this large national healthcare sample with robust admin-
istrative, medication and vital signs data, deintensifying
antihypertensive treatment in older patients with tightly
controlled SBP (baseline treated SBP <130 mmHg) was not
associated with a lower risk of fall injury or syncope. Given
higher mortality and more severe baseline cardiovascular
disease severity among patients with deintensification, it is
likely that patients' declining clinical state, which was inad-
equately recognized in the administrative data, may have
both prompted attempts at deintensification and led to
adverse events. Trial research will be needed to over-
come these limitations of observational data, before we
can conclude that treatment can be safely deintensified
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